TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05151653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05524246
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive pravastatin orally once daily through the first 35 days after bone marrow transplant.
Study: NCT06121479
Drug: Branched-chain amino acid
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral branched-chain amino acid is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
Study: NCT06405776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2μg/kg, granisetron 12mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
Study: NCT06555822
Drug: AZD5004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.
Study: NCT04807972
Drug: modified FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT06387394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injections
Study: NCT05819710
Drug: TS-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 5 mg of TS-142
Study: NCT05819710
Drug: TS-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of 10 mg of TS-142
Study: NCT05819710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of placebo
Study: NCT05956314
Drug: KM-001 cream 1% 12 weeks treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 84 days. IMP will be applied on the plantar surfaces.
Study: NCT05975021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion via a syringe pump. Total duration 48 hours.
Study: NCT06045481
Drug: administration of single dose of doxycycline
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postexposure prophylaxis with Single Dose doxycycline
Study: NCT05842395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with distal radius fractures will take daily Placebo orally for three months.
Study: NCT05072782
Drug: Immunosuppressors (Thiopurines or Methotrexate)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stratification 1 : No treatments~Stratification 2 : Immunosuppressors at same dose
Study: NCT04864418
Drug: AST-021p
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 priming immunization (2weeks x3) in 4 cohort groups (1.2mg, 2.4mg, 3.6mg and 4.8mg AST-021p) if possible, 3 boosting immunization (4weeks x 3) in cohort groups after priming immunization
Study: NCT05351021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice daily for treatment period
Study: NCT05957978
Drug: LXE408
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets
Study: NCT05957978
Drug: Paromomycin
Normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage/Administration: paromomycin 15 mg/kg/day IM q.d.
Study: NCT05956314
Drug: KM-001 cream 1% 16 weeks treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 112 days. IMP will be applied on the plantar surfaces.
Study: NCT05026008
Drug: SR1375
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water
Study: NCT05026008
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water
Study: NCT04589325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Placebo will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months.
Study: NCT05636826
Drug: atherolive-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
Study: NCT05636826
Drug: Placebo Atherolive
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.
Study: NCT06441565
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.8 g/m² (400mg bolus + 2.4g/m² continuous infusion) given every 2 weeks through hepatic arterial infusion
Study: NCT05030324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
Study: NCT05924971
Drug: Aspirin 81Mg Ec Tab
Normalized name: ASPIRIN 81MG EC TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
Study: NCT04918576
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL topical of 0.9% normal saline
Study: NCT05333328
Drug: Ovarian function suppression with endocrine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~* Either goserelin acetate or leuprorelin Acetate is allowed.~* These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~* Chemotherapy is omitted in these patients.
Study: NCT06558539
Drug: Standard Medication Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group will maintain their usual medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration remaining consistent throughout the study. No additional interventions will be provided.
Study: NCT06154538
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX chemotherapy
Study: NCT05096052
Drug: Galactomannan
Normalized name: Galactomannan Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
Study: NCT05096052
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A blinded matching placebo containing inert chemistry not able to recognise and bind to the galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
Study: NCT05377203
Drug: Quadruple combination of half doses therapy→Dual combination of standard dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.~Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.
Study: NCT06252220
Drug: Placebo to DA-1726
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05752305
Drug: MethylPREDNISolone 40 Mg/mL Injectable Suspension
Normalized name: methylPREDNISolone 40 mg/mL injectable suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
Study: NCT06226454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for oral administration.
Study: NCT05377203
Drug: Dual combination of standard dose therapy→ Quadruple combination of half doses therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.~Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.
Study: NCT04433533
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of Rosuvastatin 20mg Monotherapy.
Study: NCT04433533
Drug: Rosuvamibe 10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin10mg/ezetimibe 10mg combination Therapy
Study: NCT03805607
Drug: Ketorolac Tromethamine 30 MG/ML
Normalized name: ketorolac tromethamine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg
Study: NCT03805607
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT06600022
Drug: SCTB41
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTB41 of different doses,IV,every 3 weeks
Study: NCT06141486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for IV infusion
Study: NCT06141486
Drug: MRI contrast-enhancing agents
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, as per respective label
Study: NCT06481553
Drug: first line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel liposome in combination with trastuzumab (or trastuzumab biosimilar, or pyrotinib) ± pertuzumab ± other chemotherapy drugs (such as capecitabine, carboplatin, gemcitabine) may be used for HER-2 positive patients, with the addition of endocrine therapy for triple-positive patients.
Study: NCT05651022
Drug: Decoy20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.
Study: NCT06044311
Drug: Standard of Care Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy treatment as per standard of care.
Study: NCT06648304
Drug: TTYP01 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (60 mg) of investigational drug each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
Study: NCT06648304
Drug: Placebo (Simulant TTYP01 Tablets)
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (0 mg) of placebo each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
Study: NCT06648668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily \[QD\] × 14 days
Study: NCT04821284
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04821284
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05079854
Drug: Intraocular Instillation Solution
Normalized name: Carbachol Intraocular Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral Moxifloxacin 0.5%
Study: NCT05695248
Drug: STAR-0215
Normalized name: STAR FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAR-0215 will be administered as a subcutaneous bolus injection.
Study: NCT05055791
Drug: SYHX1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHX1903 tablets, orally, qd
Study: NCT06484192
Drug: Naproxen 500 Mg
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants will receive Naproxen (500 mg) to take for 7 days after surgery as needed
Study: NCT06484192
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants will receive Ketorolac (15 mg) immediately after surgery
Study: NCT06148194
Drug: 0.9% NaCl physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 30 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 30 mL-bottle that is used for probiotic 1 and 2.
Study: NCT06154382
Drug: Eltroxin administration
Normalized name: Fluroxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: eltroxin administration
Study: NCT06375343
Drug: PRO-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution.
Study: NCT05749211
Drug: Huaier granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity
Study: NCT06303921
Drug: 11C-M503 PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-M503
Study: NCT05699239
Drug: TS-172 10mg bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of TS-172 10 mg bid
Study: NCT05394350
Drug: MK-1088
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05699239
Drug: TS-172 30mg bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of TS-172 30 mg bid
Study: NCT05699239
Drug: TS-172 60mg bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of TS-172 60 mg bid
Study: NCT05699239
Drug: TS-172 20mg tid
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of TS-172 20 mg tid
Study: NCT05699239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of placebo
Study: NCT04524442
Drug: arginine/lysine
Normalized name: arginine/lysine ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 milliliters (mL) administered at a constant rate of 250 mL per hour
Study: NCT04486378
Drug: RO7198457 intravenous (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.
Study: NCT06102915
Drug: Nimbex 10 MG in 5 ML Injection
Normalized name: Nimbex 10 MG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative
Study: NCT05958277
Drug: Vitamin B3
Normalized name: VITAMIN B3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B3 upto 16 mg/day
Study: NCT05355610
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic gentamicin and dexamethasone administered in two doses one week apart
Study: NCT05142592
Drug: IPG7236
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
Study: NCT05834569
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group will be administered equal amounts of normal saline at the same time points.
Study: NCT06206265
Drug: TRYP-0082
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
Study: NCT06061731
Drug: low-frequency acupoint electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: In order to determine the efficacy of low-frequency acupoint electrical stimulation and electroacupuncture to improve thumb to finger action after stroke
Study: NCT05285644
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular administration of one drop in both eyes BID for 90 days.
Study: NCT05942053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo match vitamin K2 capsules once per day.
Study: NCT05942053
Drug: Vitamin K 2
Normalized name: vitamin K 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with vitamin K2 (menaquinone-7) 90 mcg/day.
Study: NCT06654791
Drug: [14C] SIM0270 Oral Preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use according to the prescribed protocol
Study: NCT04931420
Drug: Standard of Care Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: * If you have cancer of the stomach or food pipe (esophagus): the preferred chemotherapy regimen includes two or three medications. These drugs include Cisplatin or Oxaliplatin and 5-fluorouracil (5 FU) in combination with Docetaxel.~* If you have cancer of the pancreas or ampulla: the preferred chemotherapy medicines include Gemcitabine or a three-drug combination chemotherapy called FOLFIRINOX, which includes 5FU, Leucovorin, Irinotecan, and Oxaliplatin.~* If you have bile duct cancers: a combination of Gemcitabine, platinum agents, or fluoropyrimidine will be considered.
Study: NCT05766501
Drug: DOR/ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet of 100 mg doravirine (DOR)/0.25 mg islatravir (ISL) taken once daily
Study: NCT06220279
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each were monitored for pain within 24 hours
Study: NCT05414877
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vasopressor
Study: NCT05669599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo by SC injection.
Study: NCT05363891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03877874
Drug: Aironyl syrup(Terbutaline sulfate) + Epidrone syrup(Dexamethone)
Normalized name: nafronyl
DrugBank: Naftidrofuryl (DB13588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)
Study: NCT05232045
Drug: Automated urinary output collection system group (tight monitoring of urine output)
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated urinary output collection system group (tight monitoring of urine output)
Study: NCT05806359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05092711
Drug: Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
Study: NCT05970718
Drug: REGN7544
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration